Increased plasma fructosamine concentrations in laminitic horses
Version of Record online: 23 JUN 2011
© 2011 EVJ Ltd
Equine Veterinary Journal
Volume 44, Issue 2, pages 226–229, March 2012
How to Cite
KNOWLES, E. J., WITHERS, J. M. and MAIR, T. S. (2012), Increased plasma fructosamine concentrations in laminitic horses. Equine Veterinary Journal, 44: 226–229. doi: 10.1111/j.2042-3306.2011.00419.x
- Issue online: 6 FEB 2012
- Version of Record online: 23 JUN 2011
- [Paper received for publication 22.12.10; Accepted 08.04.11]
Reasons for performing study: The use of plasma fructosamine concentration ([fructosamine]) as a marker of abnormal glucose homeostasis in laminitic horses has not been investigated.
Hypothesis: Plasma fructosamine concentration may be higher amongst laminitic horses than normal horses; this might relate to underlying insulin resistance.
Objectives: 1) To compare [fructosamine] between laminitic and normal horses. 2) To investigate associations between [fructosamine] at presentation in laminitic horses with a) single sample markers of insulin resistance and b) outcome.
Methods: Plasma fructosamine concentration, fasting serum insulin concentration (insulin) and fasting plasma glucose concentration (glucose) were measured in 30 horses that presented with laminitis. Clinical details and follow-up data were recorded. Plasma fructosamine concentration was also measured in 19 nonlaminitic control horses.
Results: Laminitic horses had significantly higher mean [fructosamine] than normal horses (P<0.001). Thirteen of 30 laminitic horses had fasting hyperinsulinaemia, 2/30 had fasting hyperglycaemia. Statistically significant univariable correlations were identified between [fructosamine] and [glucose], [insulin] and the proxies RISQI and MIRG. Trends for association between [fructosamine] and negative outcome did not reach statistical significance.
Conclusions and potential relevance: Increased mean [fructosamine] in laminitic horses may represent abnormal glycaemic control and [fructosamine] may become a clinically useful marker.